Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Amylyx Pharmaceuticals is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joshua Cohen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amylyx Pharmaceuticals

It is our mission to one day end the suffering caused by neurodegenerative diseases. Every day we strive for better therapies. We question the unquestioned, yet we look for simple solutions. Together, with our growing leadership team of industry veterans, physicians and scientists, we seek new perspectives from research, from each other, and most importantly, from patients and their families. We know the answer is out there. And every day brings us closer to reaching it.

To learn more about Amylyx Pharmaceuticals, visit http://amylyx.com/

Contact:
Joshua Cohen, Chief Executive Officer
617-683-0917
https://www.linkedin.com/in/joshua-cohen-87791a45/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved